capmatinib repurposed / Cyclica - LARVOL DELTA

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease. (PubMed, Sci Rep) - "Cell-based experimental assessment reveals several clinically-relevant drug repurposing candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IRAK1

[VIRTUAL] An application of an AI-based drug-repurposing platform, PolypharmDB, to uncover antiviral activity of an approved drug (ACS-Fall 2021) - "In particular, the MET inhibitor capmatinib had a potent and broad antiviral activity against several coronaviruses in a MET-independent manner. We have also proposed novel roles for host proteins such as IRAK1/4 in supporting coronavirus infection, which can inform further drug discovery studies."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IRAK1

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug (Businesswire) - "New findings accelerated by Cyclica’s drug discovery platform suggest lung cancer drug capmatinib demonstrates robust antiviral effects in experimental COVID-19 models....The discovery was made in collaboration with Ryerson University, The Vector Institute, along with other prominent Canadian research institutions...Capmatinib, an FDA-approved MET inhibitor, marketed by Novartis under the name Tabrecta, is used clinically to treat patients with (Non-Small Cell) Lung Cancer. The consortium of research institutions showed promising results when testing capmatinib in a collection of experiments evaluating viral infectivity, entry and mechanism."

Preclinical • Infectious Disease • Novel Coronavirus Disease